Cenicriviroc Mesylate

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Cenicriviroc Mesylate

CAS No. : 497223-28-6

MCE 国际站：Cenicriviroc Mesylate

产品活性：Cenicriviroc Mesylate (TAK-652 Mesylate) 是一种双重 CCR2/CCR5 拮抗剂，同时可抑制 HIV-1 和 HIV-2，具有显著的抗炎、抗感染的功效。

研究领域：GPCR/G Protein  |  Immunology/Inflammation  |  Anti-infection

作用靶点：CCR  |  HIV

In Vitro: Migration of mouse monocytes in response to carbon tetrachloride (CCL2) is reduced following pre-treatment with Cenicriviroc Mesylate (CVC) at a concentration of 1 μM. Compare to untreated and unstimulated cells, the average fold change in migrating cells (±SD) is 0.8±0.2 (p>0.05) and 0.7±0.4 (p>0.05) for CCL2-stimulated cells treated with Cenicriviroc Mesylate and unstimulated cells treated with Cenicriviroc Mesylate, respectively. Phenotypic susceptibility testing shows, for the four R5-tropic HIV-2 isolates, a median EC₅₀ for Cenicriviroc Mesylate of 0.39 nM (0.03, 0.33, 0.45 and 0.98 nM). The dual-tropic and the X4-tropic HIV-2 strains are resistant to Cenicriviroc Mesylate with EC₅₀ at >1000 nM, and Maximum percentages of inhibition (MPI) at 33% and 4%, respectively.

In Vivo: Cenicriviroc Mesylate (CVC) treatment leads to dose-related decrease in monocyte/macrophage recruitment, and achieving statistical significance at doses ≥20 mg/kg/day (p<0.05). Compare to the vehicle-control group, peritoneal lavage monocyte/macrophage counts are decreased by: 5.7%, 45.2%, 76.5% and 26.0% for Cenicriviroc Mesylate 5 twice daily (BID), Cenicriviroc Mesylate20 twice daily (BID), Cenicriviroc Mesylate100 BID, Cenicriviroc Mesylate 20 once-daily (QD), respectively. Exposure to Cenicriviroc Mesylate is dose-related and correlated with the decrease in monocyte/macrophage recruitment, with Cenicriviroc Mesylate appearing to be more effective when given BID versus QD, in line with the higher plasma concentrations achieved with BID dosing and the known short half-life in mice (~2 hours).

相关产品：Drug Repurposing Compound Library Plus  |  Clinical Compound Library Plus  |  Bioactive Compound Library Plus  |  Anti-Infection Compound Library  |  GPCR/G Protein Compound Library  |  Immunology/Inflammation Compound Library  |  Clinical Compound Library  |  Antiviral Compound Library  |  Small Molecule Immuno-Oncology Compound Library  |  Drug Repurposing Compound Library  |  Endocrinology Compound Library  |  Orally Active Compound Library  |  Rare Diseases Drug Library  |  Anti-Pulmonary Fibrosis Compound Library  |  Chemokine Compound Library  |  Membrane Protein-targeted Compound Library  |  Membrane Receptor-targeted Compound Library  |  Highly Selective Inhibitors Library  |  Cytokine Inhibitors Library  |  Chloroquine  |  Doxorubicin hydrochloride  |  5-Fluorouracil  |  Q-VD-OPh  |  Valproic acid  |  Pirfenidone  |  Panobinostat  |  Shikonin  |  Hydroxyurea  |  Probenecid  |  Kaempferol  |  Plerixafor  |  Dimethyl fumarate  |  Birinapant  |  Maraviroc  |  Baicalin  |  Flavopiridol  |  Ritonavir  |  Ivermectin  |  Fasudil Hydrochloride  |  Ebselen  |  Rolipram  |  Betulinic acid  |  CK-666  |  RS 504393  |  Oleanolic Acid  |  Lysozyme from chicken egg white

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Dye Reagents  |  PROTAC  |  Isotope-Labeled Compounds